Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study
Top Cited Papers
- 14 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Japanese Journal of Ophthalmology
- Vol. 65 (3), 315-325
- https://doi.org/10.1007/s10384-021-00822-y
Abstract
Purpose Atropine eye drops prevent the progression of myopia, but their use has not been tested in the Japanese schoolchildren population. Here, we evaluate the efficacy and safety of 0.01% atropine eye drops for myopia control in Japanese children. Study design Multicenter (7 university hospitals), randomized, double-masked, placebo-controlled trial. Methods Participants were 171 Japanese schoolchildren aged 6 to 12 years, with progressive myopia, spherical equivalence (SE) of −1.00 to −6.00 diopters (D), and astigmatism of ≤1.5 D. They were randomized to receive either 0.01% atropine (n=85) or placebo (n=86) eye drops once nightly OU for 24 months. Primary and secondary efficacy endpoints were changes in SE and axial length (AL), respectively, from baseline to month 24. Results Data from 168 subjects were analyzed. At month 24, compliance was similar in both groups (atropine: 83.3%; placebo: 85.7%). The least squares mean change in SE and AL from baseline were, respectively, −1.26 D (95% confidence interval [CI]: −1.35, −1.17) and 0.63 mm (0.59, 0.67) for atropine and −1.48 D (− 1.57, −1.39) and 0.77 mm (0.73, 0.81) for placebo. Inter-group differences were 0.22 D (95% CI: 0.09, 0.35; P < 0.001) for SE and − 0.14 mm (−0.20, −0.08; P < 0.001) for AL. Three patients experienced mild allergic conjunctivitis side effects, with no inter-group difference in incidence (atropine: 2.4%; 2/84 patients; placebo: 1.4%; 1/84 patients). Conclusion With good compliance, 0.01% atropine is effective and safe for preventing the progression of childhood myopia.Keywords
Funding Information
- Eye-Lens Pte., Ltd.
This publication has 22 references indexed in Scilit:
- Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood MyopiaJournal of Ocular Pharmacology and Therapeutics, 2015
- Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2Ophthalmology, 2015
- Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%American Journal of Ophthalmology, 2014
- Pharmacology of myopia and potential role for intrinsic retinal circadian rhythmsExperimental Eye Research, 2013
- Prevalence and Risk Factors for Myopic Retinopathy in a Japanese Population: The Hisayama StudyOphthalmology, 2012
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012
- Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2%pirenzepineophthalmicgelinchildrenwithmyopiaJournal of American Association for Pediatric Ophthalmology and Strabismus, 2008
- Effect of Progressive Addition Lenses on Myopia Progression in Japanese Children: A Prospective, Randomized, Double-Masked, Crossover TrialInvestigative Ophthalmology & Visual Science, 2008
- Atropine for the Treatment of Childhood MyopiaOphthalmology, 2006
- The Quality of Life in Patients with Pathologic MyopiaJapanese Journal of Ophthalmology, 2001